Editas Medicine, Inc. (EDIT)

Market Cap	107.87M
Revenue (ttm)	32.31M
Net Income (ttm)	-237.09M
Shares Out	82.98M
EPS (ttm)	-2.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,354,772
Open	1.390
Previous Close	1.390
Day's Range	1.280 - 1.390
52-Week Range	1.120 - 7.600
Beta	1.87
Analysts	Buy
Price Target	8.08 (+521.54%)
Earnings Date	Mar 5, 2025

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors in collaboration with Bristol Myers Squibb C...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 3, 2016
• Employees: 246
• Stock Exchange: NASDAQ
• Ticker Symbol: EDIT
• Website: https://www.editasmedicine.com

Financial Performance

In 2024, Editas Medicine's revenue was $32.31 million, a decrease of -58.64% compared to the previous year's $78.12 million. Losses were -$237.09 million, 54.7% more than in 2023.

Analyst Forecast

According to 14 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is $8.08, which is an increase of 521.54% from the latest price.

Price Target

$8.08

(521.54% upside)

Analyst Consensus: Buy